InvestorsHub Logo
Followers 8
Posts 450
Boards Moderated 0
Alias Born 10/04/2010

Re: Chess Master post# 3670

Wednesday, 04/29/2020 12:30:28 PM

Wednesday, April 29, 2020 12:30:28 PM

Post# of 3835
GALT has initiated the adaptive Ph2b/Ph3 with a very favorable primary end point (progression to Varices)-it is now posted on the FDA Clinical Trials site:
https://clinicaltrials.gov/ct2/show/NCT04365868

This end point is a duplicate of the positive results in the original Ph2 CX trial and points to a strong likelihood of a success in the Ph3

I'm surprised that GALT hasn't done a Press Release yet about this but it's possible there is additional news that will be included with this.

Stock is up 13% today and this is the likely reason for that increase.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent GALT News